No Data
Bullish Outlook on Gossamer Bio's Seralutinib Efficacy and Market Potential
Oppenheimer Maintains Gossamer Bio(GOSS.US) With Buy Rating, Raises Target Price to $9
Oppenheimer analyst Andreas Argyrides maintains $Gossamer Bio(GOSS.US)$ with a buy rating, and adjusts the target price from $6 to $9.According to TipRanks data, the analyst has a success rate of 49.8
Gossamer Bio Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Gossamer Bio Announced Two Oral Presentations And Poster Presentation With Data Relevant To Seralutinib At European Respiratory Society Congress 2024
Analysts Just Made A Notable Upgrade To Their Gossamer Bio, Inc. (NASDAQ:GOSS) Forecasts
With 73% Institutional Ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) Is a Favorite Amongst the Big Guns